KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LifeMD (LFMD) EPS (Weighted Average and Diluted) (2016 - 2026)

LifeMD filings provide 12 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.12 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 33.33% to -$0.12 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.3, a 56.52% increase, with the full-year FY2025 number at -$0.3, up 53.12% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.12 in Q4 2025 for LifeMD, down from -$0.1 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.03 in Q1 2025 to a low of -$0.64 in Q2 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.2 (2023), compared with a mean of -$0.28.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 137.04% in 2021 and later surged 84.21% in 2025.
  • LifeMD's EPS (Weighted Average and Diluted) stood at -$0.63 in 2021, then skyrocketed by 36.51% to -$0.4 in 2022, then skyrocketed by 70.0% to -$0.12 in 2023, then crashed by 50.0% to -$0.18 in 2024, then soared by 33.33% to -$0.12 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.12 (Q4 2025), -$0.1 (Q3 2025), and -$0.05 (Q2 2025) per Business Quant data.